Replimune Melanoma Drug Snags Coveted FDA Approval After Yearlong Clash, Two Rejections on August 07, 2026 Accelerated Advanced Melanoma Approved Complete Response Letter IGNYTE trial melanoma drug Opdivo Phase 3 confirmatory trial Replimune RETINITIS PIGMENTOSA 1 Tudriqev United States Food and Drug Administration +
Replimune’s Twice‑Rejected Melanoma Drug Prevails in FDA Adcomm Vote on July 31, 2026 Advanced Melanoma Advisory Committees Cellular Tissue gene therapy melanoma drug nivolumab Opdivo Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +
Huyabio scores with Opdivo combo in 'milestone' skin cancer trial on July 14, 2026 Advanced Melanoma Combined Modality Therapy epigenetic immunomodifier Frequency of Responses Huyabio Malignant neoplasm of skin Metastatic melanoma nivolumab Opdivo Overall Survival Phase 2 Phase 3 Unresectable +
Eikon Therapeutics Presents Data on Clinical-Stage Programs at ASCO 2026 on June 01, 2026 Advanced Melanoma ASCO dual-agonist EIK1005 Eikon Inhibitor Meeting Mismatch Repair Deficiency Non-Small Cell Lung Carcinoma PARP1 gene TLR7/8 WRN inhibitor +
Replimune to ask FDA for re‑review of melanoma drug, as agency stands by past rejections on May 29, 2026 Accelerated Advanced Melanoma Approved Complete Response Letter IGNYTE melanoma drug nivolumab Opdivo Replimune RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +
Replimune Awaits FDA Direction After Complete Response Letter for Advanced Melanoma Therapy on August 04, 2025 Advanced Melanoma Cancer Therapeutic Procedure Complete IGNYTE trial nivolumab Replimune Response Letter RETINITIS PIGMENTOSA 1 United States Food and Drug Administration vusolimogene oderparepvec +